Evidence map›Paper›PMID 38190998›Full record

ArticleNuklearmedizin. Nuclear medicine2024

CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges.

Rudolf Werner, Alexander Haug, Christian Buske, Simon Heidegger, Anna L Illert, Florian Bassermann, Peter Herhaus, Andreas Buck, Johannes Duell, Max S Topp and 8 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nuklearmedizin. Nuclear medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 2 countries.

Rudolf WernerDepartment of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Alexander HaugClinical Department of Nuclear Medicine, University Hospital AKH Vienna, Wien, Austria.
Christian BuskeInstitute of Experimental Cancer Research, Ulm University Hospital, Ulm, Germany.
Simon HeideggerDepartment of Medicine III, School of Medicine, Technical University of Munich, Munchen, Germany.
Anna L IllertDepartment of Hematology and Oncology, Freiburg University Hospital, Freiburg, Germany.
Florian BassermannDepartment of Medicine III, School of Medicine, Technical University of Munich, Munchen, Germany.
Peter HerhausDepartment of Medicine III, School of Medicine, Technical University of Munich, Munchen, Germany.
Andreas BuckDepartment of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Johannes DuellInternal Medicine II, University Hospital Würzburg, Würzburg, Germany.
Max S ToppInternal Medicine II, University Hospital Würzburg, Würzburg, Germany.
Sabrina KrausInternal Medicine II, University Hospital Würzburg, Würzburg, Germany.
Hermann EinseleInternal Medicine II, University Hospital Würzburg, Würzburg, Germany.
Constantin LapaNuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Markus RadererDepartment of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Georg LenzDepartment of Medicine A - Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.
Stefan HabringerDepartment of Hematology, Oncology and Cancer Immunology, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charite Universitatsmedizin Berlin, Berlin, Germany.
Bastian von TresckowDepartment of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany.
Ulrich KellerDepartment of Hematology, Oncology and Cancer Immunology, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charite Universitatsmedizin Berlin, Berlin, Germany.
Universitätsklinikum Würzburg · DETechnical University of Munich · DEFreie Universität Berlin · DEHumboldt-Universität zu Berlin · DEMedical University of Vienna · ATUniversity Hospital Münster · DEUniversity Hospital Ulm · DEUniversity Medical Center Freiburg · DEUniversity of Augsburg · DEVienna General Hospital · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in a multitude of cancers, including neoplasms of hematopoietic origin. This feature can be leveraged by a theranostic approach, which provides a read-out of the actual CXCR4 expression in vivo, followed by CXCR4-targeted radioligand therapy (RLT) exerting anti-cancer as well as myeloablative efficacy. In a recent meeting of hematooncology and nuclear medicine specialists, statements on the current clinical practice and future perspectives of this innovative concept were proposed and summarized in this opinion article. Experts concluded that i) CXCR4-directed [68Ga]Ga-PentixaFor PET/CT has the potential to improve imaging for patients with marginal zone lymphoma; ii) CXCR4-targeted RLT exerts anti-lymphoma efficacy and myeloablative effects in patients with advanced, treatment-refractory T-cell lymphomas; iii) prospective trials with CXCR4-based imaging and theranostics are warranted.

Indexed as

NeoplasmsPositron Emission Tomography Computed TomographyHumansPrecision MedicineProspective StudiesReceptors, CXCR4CXCR4 protein, humanReceptors, CXCR4

Identifiers

PMID38190998
PMCPMC10963126
OpenAlexW4390686184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.